Notice of AGM

RNS Number : 8298Z

Epistem Holdings plc

15 December 2014

 



2014 Annual Report and Notice of AGM

Epistem confirms that its 2014 Annual Report and Notice of the Annual General Meeting to be held at 9.30am on Monday, 12^th January, 2015 at The Incubator Building, 48 Grafton Street, Manchester M13 9XX will be posted to shareholders on 19^th December, 2014. Copies of these documents can be found on the Company's website (www.epistem.co.uk) later today.   

For further details please contact:

Epistem Plc

Matthew Walls, CEO                                                                 [phone]

John Rylands, Financial Director                                                 [phone]

Peel Hunt LLP

James Steel                                                                               [phone]

Clare Terlow

Walbrook PR

Mike Wort                                                                                [phone]

Anna Dunphy

Notes to Editors:

About Epistem

Epistem (http://www.epistem.co.uk) is a personalised medicine and biotechnology company commercialising its technology and expertise in the areas of infectious and epithelial disease (oncology, gastrointestinal and dermatological). Epistem develops innovative diagnostics and pharmacogenomics (Genedrive^®), target discovery of novel therapeutics and contract research services for drug development companies. Epistem operates three divisions, Personalised Medicine (Diagnostics and Pharmacogenomics), Contract Research Services and Novel Therapies.

Genedrive® (http://www.genedrive.com) provides a major advance in next-generation molecular diagnostic testing by providing a handheld, rapid, low-cost, simple-to-use 'point of care' device with high sensitivity and specificity for diagnosis of infectious diseases. Genedrive® aims to provide a 'gold standard' identification of tuberculosis and antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs.

Epistem's Genedrive®platform has applications across a wide range of bacterial, viral and fungal and somatic mutation diseases for which Epistem is developing a menu of diagnostic tests.

 

END

 

 

NOAFFLFWIFLSEEE